Is the FDA Too Cautious?
Open to Debate
The FDA's Response to Pressure
Peter Lorry and Colin Hill: Is the FDA too cautious? John Donven: I think that you perhaps misunderstand the way the FDA does experience pressure. Most of the time when a drug kills people, take Vioxx, for example, right? And if you take it to court on that basis, you are not going to win your malpractice or product liability case. In Congress, the pressure is not on the safety side anymore. It's on the business-friendly efficacy side. That's what the agency's responded to.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
